SCHEMBL2016800

SCHEMBL2016800

CC1(C)CCc2ccc(-c3cccc(N4CCNCC4)n3)cc21

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 12/20 0.45
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
KARS1 Q15046 3/20 0.43
ASIC3 Q9UHC3 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCD Q05655 1/20 0.43
PIM3 Q86V86 6/20 0.42
PIM2 Q9P1W9 6/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12633191 0.93 ASIC3 (0.44) PIM1HTR3EHTR3BALDH1A1HTR3A
SCHEMBL2032620 0.93 HTR2A (0.45) PIM1HTR3EHTR3BALDH1A1HTR3A
SCHEMBL2014630 0.88 RARA (0.51) PIM1HTR3EHTR3BALDH1A1HTR3A
SCHEMBL12632544 0.86 ASIC3 (0.45) PIM1HTR3EHTR3BALDH1A1HTR3A
SCHEMBL2013665 0.84 IRAK4 (0.49) PIM1HTR3EHTR3BALDH1A1HTR3A
SCHEMBL2039478 0.83 HTR3E (0.46) PIM1HTR3EHTR3BALDH1A1HTR3A
SCHEMBL27872046 0.82 RARA (0.46) PIM1PIM2
SCHEMBL8515452 0.80 RARA (0.44) PIM1HTR3EHTR3BALDH1A1HTR3A
SCHEMBL12633911 0.79 HTR1A (0.44) PIM1PIM2HTR2AHTR2C
SCHEMBL12633211 0.78 HTR1A (0.43) PIM1PIM2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
CN-102666489-B Sphingosine kinase inhibitors MERCK PATENT GMBH 2014-07-23 CN disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
CN-102666489-A Sphingosine kinase inhibitors MERCK PATENT GMBH 2012-09-12 CN disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 PIM1 653/4885HTR3E 1908/4885HTR3B 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.